Brandon A Kemp1, Nancy L Howell1, John J Gildea1, Susanna R Keller1, Shetal H Padia1, Robert M Carey2. 1. From the Departments of Medicine (B.A.K., N.L.H., S.R.K., S.H.P., R.M.C.) and Pathology (J.J.G.), University of Virginia Health System, Charlottesville. 2. From the Departments of Medicine (B.A.K., N.L.H., S.R.K., S.H.P., R.M.C.) and Pathology (J.J.G.), University of Virginia Health System, Charlottesville. rmc4c@virginia.edu.
Abstract
RATIONALE: Compound 21 (C-21) is a highly selective nonpeptide AT2 receptor (AT2R) agonist. OBJECTIVE: To test the hypothesis that renal proximal tubule AT2Rs induce natriuresis and lower blood pressure in Sprague-Dawley rats and mice. METHODS AND RESULTS: In rats, AT2R activation with intravenous C-21 increased urinary sodium excretion by 10-fold (P<0.0001); this natriuresis was abolished by direct renal interstitial infusion of specific AT2R antagonist PD-123319. C-21 increased fractional excretion of Na(+) (P<0.05) and lithium (P<0.01) without altering renal hemodynamic function. AT2R activation increased renal proximal tubule cell apical membrane AT2R protein (P<0.001) without changing total AT2R expression and internalized/inactivated Na(+)-H(+) exchanger-3 and Na(+)/K(+)ATPase. C-21-induced natriuresis was accompanied by an increase in renal interstitial cGMP (P<0.01); C-21-induced increases in urinary sodium excretion and renal interstitial cGMP were abolished by renal interstitial nitric oxide synthase inhibitor l-N(6)-nitroarginine methyl ester or bradykinin B2 receptor antagonist icatibant. Renal AT2R activation with C-21 prevented Na(+) retention and lowered blood pressure in the angiotensin II infusion model of experimental hypertension. CONCLUSIONS: AT2R activation initiates its translocation to the renal proximal tubule cell apical membrane and the internalization of Na(+)-H(+) exchanger-3 and Na(+)/K(+)ATPase, inducing natriuresis in a bradykinin-nitric oxide-cGMP-dependent manner. Intrarenal AT2R activation prevents Na(+) retention and lowers blood pressure in angiotensin II-dependent hypertension. AT2R activation holds promise as a renal proximal tubule natriuretic/diuretic target for the treatment of fluid-retaining states and hypertension.
RATIONALE: Compound 21 (C-21) is a highly selective nonpeptide AT2 receptor (AT2R) agonist. OBJECTIVE: To test the hypothesis that renal proximal tubule AT2Rs induce natriuresis and lower blood pressure in Sprague-Dawley rats and mice. METHODS AND RESULTS: In rats, AT2R activation with intravenous C-21 increased urinary sodium excretion by 10-fold (P<0.0001); this natriuresis was abolished by direct renal interstitial infusion of specific AT2R antagonist PD-123319. C-21 increased fractional excretion of Na(+) (P<0.05) and lithium (P<0.01) without altering renal hemodynamic function. AT2R activation increased renal proximal tubule cell apical membrane AT2R protein (P<0.001) without changing total AT2R expression and internalized/inactivated Na(+)-H(+) exchanger-3 and Na(+)/K(+)ATPase. C-21-induced natriuresis was accompanied by an increase in renal interstitialcGMP (P<0.01); C-21-induced increases in urinary sodium excretion and renal interstitialcGMP were abolished by renal interstitialnitric oxide synthase inhibitor l-N(6)-nitroarginine methyl ester or bradykinin B2 receptor antagonist icatibant. Renal AT2R activation with C-21 prevented Na(+) retention and lowered blood pressure in the angiotensin II infusion model of experimental hypertension. CONCLUSIONS:AT2R activation initiates its translocation to the renal proximal tubule cell apical membrane and the internalization of Na(+)-H(+) exchanger-3 and Na(+)/K(+)ATPase, inducing natriuresis in a bradykinin-nitric oxide-cGMP-dependent manner. Intrarenal AT2R activation prevents Na(+) retention and lowers blood pressure in angiotensin II-dependent hypertension. AT2R activation holds promise as a renal proximal tubule natriuretic/diuretic target for the treatment of fluid-retaining states and hypertension.
Authors: Russell D Brown; Lucinda M Hilliard; Geoffrey A Head; Emma S Jones; Robert E Widdop; Kate M Denton Journal: Hypertension Date: 2011-11-28 Impact factor: 10.190
Authors: Huiping Li; Eric T Weatherford; Deborah R Davis; Henry L Keen; Justin L Grobe; Alan Daugherty; Lisa A Cassis; Andrew M Allen; Curt D Sigmund Journal: Am J Physiol Regul Integr Comp Physiol Date: 2011-07-13 Impact factor: 3.619
Authors: Nilberto R F Nascimento; Brandon A Kemp; Nancy L Howell; John J Gildea; Cláudia F Santos; Thurl E Harris; Robert M Carey Journal: Hypertension Date: 2011-04-11 Impact factor: 10.190
Authors: Shetal H Padia; Brandon A Kemp; Nancy L Howell; Susanna R Keller; John J Gildea; Robert M Carey Journal: Hypertension Date: 2011-12-27 Impact factor: 10.190
Authors: Brandon A Kemp; John F Bell; Daniele M Rottkamp; Nancy L Howell; Weijian Shao; L Gabriel Navar; Shetal H Padia; Robert M Carey Journal: Hypertension Date: 2012-06-11 Impact factor: 10.190
Authors: Lucinda M Hilliard; Emma S Jones; U Muscha Steckelings; Thomas Unger; Robert E Widdop; Kate M Denton Journal: Hypertension Date: 2011-12-12 Impact factor: 10.190
Authors: Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas Journal: Pharmacol Rev Date: 2015-10 Impact factor: 25.468
Authors: Brandon A Kemp; Nancy L Howell; Susanna R Keller; John J Gildea; Shetal H Padia; Robert M Carey Journal: Circ Res Date: 2016-06-20 Impact factor: 17.367